Transgene Announces 2026 Financial Calendar
The biotechnology company based in Strasbourg, Transgene, revealed on Tuesday, February 4th in the late afternoon, the publication dates of its financial results for the fiscal year 2026 and its annual general meeting.
Scheduled Financial Disclosures
According to the press release, the group specializing in viral vector-based immunotherapies for cancer will publish its annual results for 2025 on March 24th. The first quarter accounts of 2026 will be released on April 29th, followed by the general meeting of shareholders scheduled for May 13th. The company also indicates that the half-year results will be presented on September 24th, while the third quarter results will be announced on November 9th, 2026. This provisional calendar thus structures the regular financial information of the group throughout the year. The company, listed on Euronext Paris under the code TNG, did not provide any details on its performance or strategic orientations during this purely calendar-related announcement.
Ongoing Clinical Developments
According to the document, Transgene is developing several immunotherapies in clinical phase based on viral vectors. The main candidate, TG4050, derived from its myvac platform, is an individualized treatment that has achieved clinical proof of concept in patients with adjuvant head and neck cancer, the group specifies. Additionally, the company mentions BT-001, an oncolytic virus developed from its invir.IO platform, currently in clinical development. According to the press release, the myvac platform allows the integration of tumor mutations identified and selected through artificial intelligence technologies, in a personalized therapeutic vaccination approach. The invir.IO platform aims to design next-generation multifunctional oncolytic viruses.
Company Focus and Research Programs
The group indicates that it is based in Strasbourg and focuses its activities on the design and development of immunotherapy products against cancers. Transgene specifies that it continues other research programs exploiting its viral vector technology to fuel the development of its portfolio of therapeutic candidates. The company did not communicate any financial details or business forecasts in this document, which is strictly limited to the announcement of the communication schedule for the current year. The company remains listed on Euronext Paris, where it regularly disseminates its regulated information to investors and financial analysts.
